UA68326C2 - An attenuated strain of the virus causing the porcine reproductive and respiratory syndrom (prrs), a vaccine for porcine protection from prrs, a method for preparation of active vaccine against prrs - Google Patents
An attenuated strain of the virus causing the porcine reproductive and respiratory syndrom (prrs), a vaccine for porcine protection from prrs, a method for preparation of active vaccine against prrs Download PDFInfo
- Publication number
- UA68326C2 UA68326C2 UA97105158A UA97105158A UA68326C2 UA 68326 C2 UA68326 C2 UA 68326C2 UA 97105158 A UA97105158 A UA 97105158A UA 97105158 A UA97105158 A UA 97105158A UA 68326 C2 UA68326 C2 UA 68326C2
- Authority
- UA
- Ukraine
- Prior art keywords
- virus
- strain
- vaccine
- prrs
- attenuated
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 103
- 230000002238 attenuated effect Effects 0.000 title claims abstract description 43
- 229960005486 vaccine Drugs 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 19
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 7
- 230000001850 reproductive effect Effects 0.000 title claims abstract description 5
- 230000000241 respiratory effect Effects 0.000 title claims abstract description 5
- 238000002360 preparation method Methods 0.000 title description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 230000003612 virological effect Effects 0.000 claims description 17
- 241000282887 Suidae Species 0.000 claims description 16
- 230000010076 replication Effects 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 5
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 38
- 208000015181 infectious disease Diseases 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 241000282898 Sus scrofa Species 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 239000002356 single layer Substances 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 230000006978 adaptation Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000013553 cell monolayer Substances 0.000 description 4
- 210000003022 colostrum Anatomy 0.000 description 4
- 235000021277 colostrum Nutrition 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 208000019465 refractory cytopenia of childhood Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 210000001132 alveolar macrophage Anatomy 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 208000012153 swine disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 101100191372 Arabidopsis thaliana PRK5 gene Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000710788 Lelystad virus Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000656 anti-yeast Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 208000033937 musculocontractural type Ehlers-Danlos syndrome Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10061—Methods of inactivation or attenuation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/815—Viral vaccine for porcine species, e.g. swine
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09600168A ES2102971B1 (es) | 1996-01-25 | 1996-01-25 | Nueva cepa atenuada del virus causante del sindrome respiratorio y reproductivo porcino (prrs), las vacunas y medios de diagnostico obtenibles con la misma y los procedimientos para su obtencion. |
PCT/ES1996/000234 WO1997027288A1 (es) | 1996-01-25 | 1996-12-04 | Nueva cepa atenuada del virus causante del sindrome respiratorio y reproductivo porcino (prrs), las vacunas y medios de diagnostico obtenibles con la misma y los procedimientos para su obtencion |
Publications (1)
Publication Number | Publication Date |
---|---|
UA68326C2 true UA68326C2 (en) | 2004-08-16 |
Family
ID=8293550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA97105158A UA68326C2 (en) | 1996-01-25 | 1996-04-12 | An attenuated strain of the virus causing the porcine reproductive and respiratory syndrom (prrs), a vaccine for porcine protection from prrs, a method for preparation of active vaccine against prrs |
Country Status (13)
Country | Link |
---|---|
US (1) | US6001370A (hu) |
EP (1) | EP0835929A1 (hu) |
JP (1) | JP3068204B2 (hu) |
KR (1) | KR19980703268A (hu) |
CN (1) | CN1185806A (hu) |
BR (1) | BR9604888A (hu) |
CA (1) | CA2216436A1 (hu) |
CZ (1) | CZ286766B6 (hu) |
ES (1) | ES2102971B1 (hu) |
HU (1) | HUP9801124A3 (hu) |
PL (1) | PL185841B1 (hu) |
UA (1) | UA68326C2 (hu) |
WO (1) | WO1997027288A1 (hu) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0587780T4 (da) * | 1991-06-06 | 2008-10-13 | Boehringer Ingelheim Vetmed | Smitstof, som forårsager Mystery Swine Disease,vaccinepræparater og diagnostiske sæt |
US6380376B1 (en) * | 1992-10-30 | 2002-04-30 | Iowa State University Research Foundation | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
US6773908B1 (en) | 1992-10-30 | 2004-08-10 | Iowa State University Research Foundation, Inc. | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
US6592873B1 (en) * | 1992-10-30 | 2003-07-15 | Iowa State University Research Foundation, Inc. | Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids |
US5695766A (en) * | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
US20040224327A1 (en) * | 1996-10-30 | 2004-11-11 | Meulenberg Johanna Jacoba Maria | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
EP0839912A1 (en) * | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
EP1153139B1 (en) | 1999-02-10 | 2009-04-01 | Serono Genetics Institute S.A. | Polymorphic markers of the lsr gene |
EP1157121B1 (en) * | 1999-03-08 | 2013-04-24 | Boehringer Ingelheim Vetmedica GmbH | Prrsv replicon |
AU4482200A (en) | 1999-04-22 | 2000-11-10 | United States Department Of Agriculture | Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142 |
SG83740A1 (en) * | 1999-08-10 | 2001-10-16 | Inst Of Molecular Agrobiology | An attenuated porcine reproductive and respiratory syndrome virus strain and methods of use |
US7338787B2 (en) | 2000-01-14 | 2008-03-04 | Serono Genetics Institute S.A. | Nucleic acids encoding OBG3 globular head and uses thereof |
EP1156111A1 (en) * | 2000-05-19 | 2001-11-21 | Stichting Dienst Landbouwkundig Onderzoek | Chimeric arterivirus-like particles |
CA2427787C (en) | 2000-12-07 | 2012-07-17 | Syngenta Limited | Herbicide resistant plants |
MXPA03006818A (es) * | 2001-01-30 | 2004-10-15 | Lauridsen Group Inc | Metodos y composiciones para modular el sistema inmune de animales. |
KR20050040172A (ko) * | 2003-10-27 | 2005-05-03 | 주식회사 중앙백신연구소 | 돼지 생식기호흡기 증후군 바이러스 불활화 백신의 제조방법 |
TW200604526A (en) * | 2004-06-18 | 2006-02-01 | Unviersity Of Minnesota | Identifying virally infected and vaccinated organisms |
US7632636B2 (en) | 2004-09-21 | 2009-12-15 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome isolates and methods of use |
US8178103B2 (en) | 2004-11-19 | 2012-05-15 | Intervet International B.V. | Porcine reproductive and respiratory syndrome virus strains and compositions |
PT1904631E (pt) | 2005-06-24 | 2012-07-16 | Univ Minnesota | Vírus srrp, clones infecciosos, os seus mutantes e processos de utilização |
HUE054868T2 (hu) | 2005-12-29 | 2021-10-28 | Boehringer Ingelheim Animal Health Usa Inc | Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására |
CN100523177C (zh) * | 2007-01-09 | 2009-08-05 | 中国农业科学院哈尔滨兽医研究所 | 猪繁殖与呼吸综合症病毒弱毒疫苗株及其应用 |
US20110117129A1 (en) * | 2008-08-25 | 2011-05-19 | Boehringer Ingelheim Vetmedica, Inc. | Vaccine Against Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP PRRS) |
TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物 |
MX346636B (es) | 2011-02-17 | 2017-03-27 | Boehringer Ingelheim Vetmedica Gmbh | Procedimiento para la produccion a escala comercial de prrsv. |
DK2675475T3 (en) | 2011-02-17 | 2015-09-14 | Boehringer Ingelheim Vetmed | NEW EUROPEAN PRRSV TRIAL |
KR101281361B1 (ko) * | 2011-07-18 | 2013-07-02 | 서울대학교산학협력단 | 북미형 돼지 생식기 호흡기 증후군 바이러스 예방 백신 조성물 및 이를 포함하는 혼합백신 조성물 |
US9187731B2 (en) | 2011-07-29 | 2015-11-17 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus inducing type I interferon in susceptible cells |
WO2013017570A1 (en) | 2011-07-29 | 2013-02-07 | Boehringer Ingelheim Vetmedica Gmbh | Novel prrs virus inducing type i interferon in susceptible cells |
JP6386999B2 (ja) * | 2012-05-17 | 2018-09-05 | ゾエティス・エルエルシー | ブタ生殖および呼吸症候群(prrs)ウイルスに対する離乳前の効果的なワクチン接種 |
CA2892948C (en) | 2012-12-07 | 2022-09-20 | The Board Of Trustees Of The University Of Illinois | Porcine reproductive and respiratory syndrome virus compositions and uses thereof |
CN105073130A (zh) | 2013-03-15 | 2015-11-18 | 勃林格殷格翰动物保健公司 | 猪生殖与呼吸综合征病毒、组合物、疫苗及使用方法 |
MX2020010248A (es) | 2013-12-20 | 2020-10-16 | Boehringer Ingelheim Vetmedica Gmbh | Variante del virus prrs, clon de adnc del virus europeo y sus usos. |
MY191895A (en) | 2016-11-03 | 2022-07-18 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0587780T4 (da) * | 1991-06-06 | 2008-10-13 | Boehringer Ingelheim Vetmed | Smitstof, som forårsager Mystery Swine Disease,vaccinepræparater og diagnostiske sæt |
KR0138092B1 (ko) * | 1991-08-26 | 1998-04-30 | 제임스 씨. 데세사레 | 미확인(Mystery) 돼지 질병 관련 바이러스제 |
DE601062T1 (de) * | 1991-08-26 | 1995-05-18 | James Edward Collins | Vakzine gegen und diagnosemethode für das schweine-unfruchtbarkeits- und atmungs-syndrom (suas). |
JPH07501049A (ja) * | 1991-10-14 | 1995-02-02 | アクゾ・ノベル・エヌ・ベー | ブタ生殖・呼吸系症候群ワクチン及び診断方法 |
SK98695A3 (en) * | 1993-02-08 | 1996-11-06 | Bayer Ag | Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines |
ATE206455T1 (de) * | 1994-04-11 | 2001-10-15 | Akzo Nobel Nv | Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des schweins |
-
1996
- 1996-01-25 ES ES09600168A patent/ES2102971B1/es not_active Expired - Fee Related
- 1996-04-12 UA UA97105158A patent/UA68326C2/uk unknown
- 1996-12-04 EP EP96940665A patent/EP0835929A1/en not_active Withdrawn
- 1996-12-04 US US08/930,330 patent/US6001370A/en not_active Expired - Fee Related
- 1996-12-04 PL PL96322455A patent/PL185841B1/pl not_active IP Right Cessation
- 1996-12-04 CA CA002216436A patent/CA2216436A1/en not_active Abandoned
- 1996-12-04 BR BR9604888A patent/BR9604888A/pt not_active Application Discontinuation
- 1996-12-04 CZ CZ19973377A patent/CZ286766B6/cs not_active IP Right Cessation
- 1996-12-04 KR KR1019970706672A patent/KR19980703268A/ko active IP Right Grant
- 1996-12-04 HU HU9801124A patent/HUP9801124A3/hu unknown
- 1996-12-04 CN CN96194133A patent/CN1185806A/zh active Pending
- 1996-12-04 WO PCT/ES1996/000234 patent/WO1997027288A1/es not_active Application Discontinuation
- 1996-12-04 JP JP9526571A patent/JP3068204B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
BR9604888A (pt) | 1998-12-15 |
JPH10507372A (ja) | 1998-07-21 |
CZ337797A3 (cs) | 1998-03-18 |
PL185841B1 (pl) | 2003-08-29 |
PL322455A1 (en) | 1998-02-02 |
CN1185806A (zh) | 1998-06-24 |
CA2216436A1 (en) | 1997-07-31 |
ES2102971B1 (es) | 1998-03-01 |
WO1997027288A1 (es) | 1997-07-31 |
EP0835929A1 (en) | 1998-04-15 |
ES2102971A1 (es) | 1997-08-01 |
CZ286766B6 (en) | 2000-06-14 |
MX9707302A (es) | 1998-06-30 |
JP3068204B2 (ja) | 2000-07-24 |
KR19980703268A (ko) | 1998-10-15 |
US6001370A (en) | 1999-12-14 |
HUP9801124A3 (en) | 1999-09-28 |
HUP9801124A2 (hu) | 1998-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA68326C2 (en) | An attenuated strain of the virus causing the porcine reproductive and respiratory syndrom (prrs), a vaccine for porcine protection from prrs, a method for preparation of active vaccine against prrs | |
US5510258A (en) | Porcine reproductive and respiratory syndrome virus antigen and processes for the preparation and use of said antigen in vaccines and diagnostics | |
Seo et al. | Specific cytotoxic T lymphocytes are involved in in vivo clearance of infectious bronchitis virus | |
Afshar et al. | Viruses associated with bovine semen. | |
KR100484041B1 (ko) | 돼지생식 및 호흡증후군 바이러스의 유럽백신 균주 | |
Fulton et al. | Neutralizing antibodies to type 1 and 2 bovine viral diarrhea viruses: detection by inhibition of viral cytopathology and infectivity by immunoperoxidase assay | |
Beer et al. | Cytotoxic T-lymphocyte responses in cattle infected with bovine viral diarrhea virus | |
Salt | Persistence of foot-and-mouth disease virus | |
De Smit | Laboratory diagnosis, epizootiology, and efficacy of marker vaccines in classical swine fever: a review | |
Beer et al. | A new inactivated BVDV genotype I and II vaccine: an immunisation and challenge study with BVDV genotype I | |
Paton et al. | Foetal cross-protection experiments between type 1 and type 2 bovine viral diarrhoea virus in pregnant ewes | |
Bruschke et al. | An experimental multivalent bovine virus diarrhea virus E2 subunit vaccine and two experimental conventionally inactivated vaccines induce partial fetal protection in sheep | |
SK119498A3 (en) | Porcine reproductive and respiratory syndrome vaccine | |
Carlsson et al. | Protective effect of an ISCOM bovine virus diarrhoea virus (BVDV) vaccine against an experimental BVDV infection in vaccinated and non-vaccinated pregnant ewes | |
De Smit et al. | Recombinant classical swine fever (CSF) viruses derived from the Chinese vaccine strain (C-strain) of CSF virus retain their avirulent and immunogenic characteristics | |
Collen et al. | Single amino acid differences are sufficient for CD4+ T-cell recognition of a heterologous virus by cattle persistently infected with bovine viral diarrhea virus | |
Kortekaas et al. | Rational design of a classical swine fever C-strain vaccine virus that enables the differentiation between infected and vaccinated animals | |
CA2224309C (en) | Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection | |
Edwards et al. | Comparative studies of border disease andclosely related virus infections in experimental pigs and sheep | |
Sakoda et al. | A new assay for classical swine fever virus based on cytopathogenicity in porcine kidney cell line FS-L3 | |
Shimizu et al. | Experimental infection of pregnant goats with swine fever virus | |
McKercher | A Comparison of the Viruses of Infectious Bovine Rhinotracheitis (IBR), Infectious Pustular Vulvovaginitis (IPV), and Rinderpest: Part I. Studies of Antigenic Relationships | |
EP1543113B1 (en) | Chicken astrovirus type 2 | |
JPH08188515A (ja) | 組織培養物において効能のあるトキソプラズマ ゴンデイ ブラデイゾイトワクチンの生産 | |
Roehe | Studies on the comparative virology of pestiviruses |